BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 12452205)

  • 1. The natural history and clinical characteristics of aspirin-exacerbated respiratory disease.
    Berges-Gimeno MP; Simon RA; Stevenson DD
    Ann Allergy Asthma Immunol; 2002 Nov; 89(5):474-8. PubMed ID: 12452205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The blocking effect of essential controller medications during aspirin challenges in patients with aspirin-exacerbated respiratory disease.
    White AA; Stevenson DD; Simon RA
    Ann Allergy Asthma Immunol; 2005 Oct; 95(4):330-5. PubMed ID: 16279562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Failure of tacrolimus to prevent aspirin-induced respiratory reactions in patients with aspirin-exacerbated respiratory disease.
    Stevenson DD; Mehra PK; White AA; Gupta S; Woessner KM; Simon RA
    J Allergy Clin Immunol; 2005 Oct; 116(4):755-60. PubMed ID: 16210047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of aspirin-exacerbated respiratory disease in patients with asthma in Turkey: a cross-sectional survey.
    Bavbek S; Yilmaz I; Celik G; Aydin O; Erkekol FÖ; Orman A; Kurt E; Ediger D; Dursun B; Abadoğlu O; Ozşeker F; Akkaya E; Karakiş GP; Canbakan S; Yüksel S; Misirligil Z
    Allergol Immunopathol (Madr); 2012; 40(4):225-30. PubMed ID: 21889254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting outcomes of oral aspirin challenges in patients with asthma, nasal polyps, and chronic sinusitis.
    Dursun AB; Woessner KA; Simon RA; Karasoy D; Stevenson DD
    Ann Allergy Asthma Immunol; 2008 May; 100(5):420-5. PubMed ID: 18517072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of high-dose rofecoxib in patients with aspirin-exacerbated respiratory disease.
    Woessner KM; Simon RA; Stevenson DD
    Ann Allergy Asthma Immunol; 2004 Oct; 93(4):339-44. PubMed ID: 15521369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship between historical aspirin-induced asthma and severity of asthma induced during oral aspirin challenges.
    Williams AN; Simon RA; Woessner KM; Stevenson DD
    J Allergy Clin Immunol; 2007 Aug; 120(2):273-7. PubMed ID: 17481713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aspirin-exacerbated respiratory disease and current treatment modalities.
    Sakalar EG; Muluk NB; Kar M; Cingi C
    Eur Arch Otorhinolaryngol; 2017 Mar; 274(3):1291-1300. PubMed ID: 27538737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic Evaluation in Aspirin-Exacerbated Respiratory Disease.
    Williams AN
    Immunol Allergy Clin North Am; 2016 Nov; 36(4):657-668. PubMed ID: 27712761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of triflusal (antiplatelet drug) in patients with aspirin-exacerbated respiratory diseases.
    Fraj J; Valero A; Vives R; Pérez I; Borja J; Izquierdo I; Picado C
    Allergy; 2008 Jan; 63(1):112-5. PubMed ID: 18053020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety of celecoxib in patients with aspirin-sensitive asthma.
    Woessner KM; Simon RA; Stevenson DD
    Arthritis Rheum; 2002 Aug; 46(8):2201-6. PubMed ID: 12209526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural history and clinical features of aspirin-exacerbated respiratory disease.
    Fahrenholz JM
    Clin Rev Allergy Immunol; 2003 Apr; 24(2):113-24. PubMed ID: 12668892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Nasal polyps is not a homogenous pathology].
    Arcimowicz M; Balcerzak J; Samoliński BK
    Pol Merkur Lekarski; 2005 Sep; 19(111):276-9. PubMed ID: 16358841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rhinosinusitis and nasal polyps in aspirin-exacerbated respiratory disease.
    Mullol J; Picado C
    Immunol Allergy Clin North Am; 2013 May; 33(2):163-76. PubMed ID: 23639706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of aspirin exacerbated respiratory disease with a low salicylate diet: a pilot crossover study.
    Sommer DD; Hoffbauer S; Au M; Sowerby LJ; Gupta MK; Nayan S
    Otolaryngol Head Neck Surg; 2015 Jan; 152(1):42-7. PubMed ID: 25344589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aspirin exacerbated respiratory disease: Current topics and trends.
    Rodríguez-Jiménez JC; Moreno-Paz FJ; Terán LM; Guaní-Guerra E
    Respir Med; 2018 Feb; 135():62-75. PubMed ID: 29414455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eicosanoids, aspirin-intolerance and the upper airways--current standards and recent improvements of the desensitization therapy.
    Pfaar O; Klimek L
    J Physiol Pharmacol; 2006 Dec; 57 Suppl 12():5-13. PubMed ID: 17244950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of aspirin desensitization on novel biomarkers in aspirin-exacerbated respiratory diseases.
    Katial RK; Strand M; Prasertsuntarasai T; Leung R; Zheng W; Alam R
    J Allergy Clin Immunol; 2010 Oct; 126(4):738-44. PubMed ID: 20728206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitivity to nonsteroidal anti-inflammatory drugs.
    Namazy JA; Simon RA
    Ann Allergy Asthma Immunol; 2002 Dec; 89(6):542-50; quiz 550, 605. PubMed ID: 12487218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early effects of aspirin desensitization treatment in asthmatic patients with aspirin-exacerbated respiratory disease.
    Berges-Gimeno MP; Simon RA; Stevenson DD
    Ann Allergy Asthma Immunol; 2003 Mar; 90(3):338-41. PubMed ID: 12669898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.